4-(3-methyl-1H-1,2,4-triazol-5-yl)piperidine | 933713-90-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-(3-methyl-1H-1,2,4-triazol-5-yl)piperidine
• 英文别名: 4-(5-methyl-1H-1,2,4-triazol-3-yl)piperidine
• CAS: 933713-90-7
• 化学式: C₈H₁₄N₄
• mdl: MFCD14610792
• 分子量: 166.22
• InChiKey: DVYSYRXOUIBQJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  53.6
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR CGRP
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2018178938A1

  公开（公告）日：2018-10-04

  The disclosures herein relate to novel compounds of formula (IA) wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function. The disclosures herein also relates to novel compounds of formula(IB) wherein R1, R2 and R3 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function. The disclosures herein also relate to novel compounds of formula (IC) wherein Ar1 and R1 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

  本公开涉及式(I A)的新化合物，其中R1、R2、R3和R4如本文所定义，并其在治疗、预防、改善、控制或减少与CGRP受体功能相关的脑血管或血管疾病中的用途。本公开还涉及到式(IB)的新化合物，其中R1、R2和R3如本文所定义，并其在治疗、预防、改善、控制或减少与CGRP受体功能相关的脑血管或血管疾病中的用途。本公开还涉及到式(IC)的新化合物，其中Ar1和R1如本文所定义，并其在治疗、预防、改善、控制或减少与CGRP受体功能相关的脑血管或血管疾病中的用途。
• CGRP receptor antagonists
  申请人：Heptares Therapeutics Limited

  公开号：US10166226B2

  公开（公告）日：2019-01-01

  The disclosures herein relate to novel compounds of formula wherein Ar1 and R1 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

  本文所披露的内容涉及新型式化合物 其中 Ar1 和 R1 如本文所定义，以及它们在治疗、预防、改善、控制或减少与 CGRP 受体功能相关的脑血管或血管疾病中的用途。
• CGRP RECEPTOR ANTAGONISTS
  申请人：Heptares Therapeutics Limited

  公开号：US20170121311A1

  公开（公告）日：2017-05-04

  The disclosures herein relate to novel compounds of formula wherein Ar 1 and R 1 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
• CGRP Receptor Antagonists
  申请人：Heptares Therapeutics Limited

  公开号：US20170239236A1

  公开（公告）日：2017-08-24

  The disclosures herein relate to novel compounds of formula wherein Ar 1 and R 1 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
• US9688660B2
  申请人：——

  公开号：US9688660B2

  公开（公告）日：2017-06-27